Liraglutide's acute central and peripheral metabolic effects are being investigated in healthy individuals

While type 2 diabetes and obesity are primary indications for GLP-1 receptor agonists like Liraglutide, growing evidence points to GLP-1's significant impact on brain function. This includes modulating reward processing and various cognitive functions. However, the acute influence of GLP-1 administration on systemic and brain metabolism, and its subsequent modulation of brain signaling and behavior, particularly in healthy individuals, remains an area requiring deeper investigation. Understanding these central effects could unlock new therapeutic avenues for brain health beyond traditional metabolic benefits.

This study aims to investigate the acute effects of Liraglutide, a GLP-1 receptor agonist, on brain metabolism, brain network function, executive functioning, and mood. The research will involve healthy, normal-weight individuals. The study design focuses on assessing how acute GLP-1 administration influences systemic and brain metabolism to modulate brain signaling and behavior. Specific doses, routes, frequencies, and durations of Liraglutide administration, as well as the exact methods for measuring brain and systemic changes, are not detailed in this abstract.